echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Arthritis Rheumatol: Efficacy, safety and pharmacodynamic effects of Bruton's tyrosine kinase inhibitor Fenebrutinib in the treatment of systemic lupus erythematosus

    Arthritis Rheumatol: Efficacy, safety and pharmacodynamic effects of Bruton's tyrosine kinase inhibitor Fenebrutinib in the treatment of systemic lupus erythematosus

    • Last Update: 2022-04-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com


    immunity




    rheumatoid arthritis



    Figure 1: Changes in plasma blast gene signatures in patients with systemic lupus erythematosus treated with placebo, fenebrutinib 150 mg once daily (Qd), or fenebrutinib 200 mg twice daily (Bid)


     

    Figure 2.


    screening


    Source:Isenberg D, Furie R, Jones NS, Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo- Controlled Trial.


     Isenberg D, Furie R, Jones NS, Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.




    leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.